Skip to main content

Table 1 Clinicopathologic characteristics of high-grade osteosarcoma patients and IHC of six biomarkers

From: Prognostic value of tumor suppressors in osteosarcoma before and after neoadjuvant chemotherapy

Variables nBX %BX nRX %RX
All high grade osteosarcoma 48 100 47 100
Neoadjuvant chemotherapy 48 100 47 100
Sex     
Female 19 40 17 36
Male 29 60 30 64
Patient age     
<10 years 10 21 9 19
10–24 years 31 65 31 66
>24 years 7 15 7 15
Histological subtype     
Osteoblastic 34 71 33 70
Chondroblastic 4 8 7 15
Fibroblastic 5 10 4 9
Telangiectatic 5 10 3 6
Location     
Tibia / Fibula / Calcaneus 19 40 15 32
Femur 18 38 20 43
Humerus / Ulna 6 13 5 11
Axial 5 10 7 15
Pathologic Response     
Responder 26 54 24 49
Non-Responder 22 46 23 51
Metastasis     
Yes 21 44 18 38
No 27 56 29 62
P16 total (n matchedBX-RX  = 27) 44 100 39 100
P16positive 25 57 17 44
P16negative 19 43 22 56
P53 total (n matchedBX-RX  = 31) 47 100 44 100
P53positive 9 19 12 27
P53negative 38 81 32 73
PTEN total (n matchedBX-RX  = 10) 40 100 22 100
PTENpositive 25 63 7 32
PTENnegative 15 37 15 68
Maspin total (n matchedBX-RX  = 21) 39 100 33 100
Maspinpositive 26 67 10 30
Maspinnegative 13 33 23 70
Ki67 total (n matchedBX-RX  = 15) 43 100 25 100
Ki67positive 24 56 8 32
Ki67negative 19 44 17 68
BMI1 total (n matchedBX-RX  = 16) 42 100 28 100
BMI1positive 11 26 2 7
BMI1negative 31 74 26 93
  1. BX biopsy, RX resection